2006
A Prospective Trial of Radiation Alone vs Combination Chemotherapy Alone for Early-Stage Hodgkin's Disease: Implications of 25-Year Follow-Up to Current Combined Modality Therapy.
Longo D, Glatstein E, Duffey P, Young R, Fiem S, Jaffe E, Camphausen K, Wilson W, DeVita V. A Prospective Trial of Radiation Alone vs Combination Chemotherapy Alone for Early-Stage Hodgkin's Disease: Implications of 25-Year Follow-Up to Current Combined Modality Therapy. Blood 2006, 108: 98. DOI: 10.1182/blood.v108.11.98.98.Peer-Reviewed Original ResearchStage IA diseaseDisease-free survivalComplete responseModality therapyHodgkin's diseaseRadiation therapyMOPP chemotherapyFirst remissionIA diseaseOverall survivalSecond cancersSignificant treatment toxicityStage Hodgkin's diseaseCombined modality therapyRadiation-treated patientsIIIA Hodgkin's diseaseAdministration of radiationInitial remissionProspective trialTreatment toxicityCombination chemotherapyIA patientsLate effectsPatientsMOPP
1999
The lymphomas.
DeVita V, Canellos G. The lymphomas. Seminars In Hematology 1999, 36: 84-94. PMID: 10595757.Peer-Reviewed Original ResearchHodgkin's disease and transplantation: a room with a (nontransplanter's) view.
Marshall N, DeVita V. Hodgkin's disease and transplantation: a room with a (nontransplanter's) view. Seminars In Oncology 1999, 26: 67-73. PMID: 10073563.Peer-Reviewed Original ResearchConceptsHigh-dose chemotherapyPeripheral blood stem-cellHodgkin's diseaseOverall survivalRefractory diseaseDisease-freeBone marrowPeripheral blood stem-cell supportGraft-versus-host disease prophylaxisManagement of refractory diseasePatients potential candidatesImprove disease-freePatients disease-freeFollow-up timeShort follow-up timeResponse to treatmentSalvage chemotherapyApproach to treatmentCombination chemotherapyDose intensityTransplant supportAllograft patientsInitial remissionRelapse rateDisease prophylaxis
1997
Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
Longo D, Glatstein E, Duffey P, Young R, Ihde D, Bastian A, Wilson W, Wittes R, Jaffe E, Hubbard S, DeVita V. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease. Journal Of Clinical Oncology 1997, 15: 3338-46. PMID: 9363863, DOI: 10.1200/jco.1997.15.11.3338.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildCombined Modality TherapyDacarbazineDisease-Free SurvivalDoxorubicinFemaleHodgkin DiseaseHumansMaleMechlorethamineMediastinal NeoplasmsMiddle AgedPrednisoneProcarbazineProspective StudiesTreatment OutcomeVinblastineVincristineConceptsMantle field radiation therapyDisease-free survivalLarge mediastinal massMediastinal Hodgkin's diseaseHodgkin's diseaseABVD chemotherapyRadiation therapyOverall survivalMediastinal massMOPP/ABVDSecond solid tumorsTreatment-related pneumonitisComplete response rateAnn Arbor stageClinical prognostic factorsErythrocyte sedimentation rateTreatment of patientsAge 35 yearsLactate dehydrogenase levelsABVD therapyDacarbazine (ABVD) chemotherapyMedian followMOPP chemotherapySalvage therapyB symptomsLate sequelae of treatment of Hodgkin's disease
DeVita V. Late sequelae of treatment of Hodgkin's disease. Current Opinion In Oncology 1997, 9: 428-431. PMID: 9327220, DOI: 10.1097/00001622-199709050-00006.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseEarly-stage Hodgkin's diseaseLow-dose radiotherapyStage Hodgkin's diseaseRadiation treatment fieldLate sequelaeSecond malignanciesCombination chemotherapySuccessful treatmentClinical trialsFull dosesBreast cancerLeukemia riskSolid tumorsLow dosesYoung womenDiseaseChemotherapyTreatmentDosesTreatment fieldEarlier reportsRiskYearsReport
1993
Is alternating cyclic chemotherapy better than standard four-drug chemotherapy for Hodgkin's disease? No.
DeVita V. Is alternating cyclic chemotherapy better than standard four-drug chemotherapy for Hodgkin's disease? No. Important Advances In Oncology 1993, 197-208. PMID: 8505053.Peer-Reviewed Original Research
1992
Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure.
Longo D, Duffey P, Young R, Hubbard S, Ihde D, Glatstein E, Phares J, Jaffe E, Urba W, DeVita V. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. Journal Of Clinical Oncology 1992, 10: 210-8. PMID: 1732422, DOI: 10.1200/jco.1992.10.2.210.Peer-Reviewed Original ResearchConceptsComplete response rateInitial remissionComplete remissionCombination chemotherapyHodgkin's diseaseSalvage therapyOverall survivalPeripheral blood stem cell supportResponse rateChemotherapy-induced complete remissionConventional-dose salvage therapyDate of relapseDurable second remissionsRemission 5 yearsSalvage combination chemotherapyShort initial remissionTreatment-related complicationsDisease-free survivalClinical prognostic factorsStem cell supportDuration of responsePrimary treatment regimenRelapse of patientsNational Cancer InstituteB symptoms
1991
Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP.
Longo D, Duffey P, DeVita V, Wiernik P, Hubbard S, Phares J, Bastian A, Jaffe E, Young R. Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP. Journal Of Clinical Oncology 1991, 9: 1409-20. PMID: 1712836, DOI: 10.1200/jco.1991.9.8.1409.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBleomycinDose-Response Relationship, DrugDoxorubicinFemaleFollow-Up StudiesHodgkin DiseaseHumansLeukemiaLomustineMaleMechlorethamineMiddle AgedNeoplasm StagingPrednisoneProcarbazineRemission InductionStreptozocinSurvival RateVincristineConceptsAdvanced-stage Hodgkin's diseaseErythrocyte sedimentation rateDose intensityOverall survivalHodgkin's diseaseInitial erythrocyte sedimentation rateDisease-free survival ratesDisease-free survival curvesComplete response rateDisease-free survivalBetter overall survivalPoor prognostic factorSecondary acute leukemiaHigher platelet countsAssessable patientsPrognostic factorsPlatelet countAcute leukemiaTreatment outcomesMOPPPatientsResponse rateSurvival rateSurvival curvesDiseaseTreatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment.
Longo D, Russo A, Duffey P, Hubbard S, Glatstein E, Hill J, Jaffe E, Young R, DeVita V. Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment. Journal Of Clinical Oncology 1991, 9: 227-35. PMID: 1988570, DOI: 10.1200/jco.1991.9.2.227.Peer-Reviewed Original ResearchConceptsMediastinal Hodgkin's diseaseDisease-free survivalComplete respondersModality treatmentHodgkin's diseaseNational Cancer InstituteComplete remissionRadiation therapyMantle radiation therapyStage IIB diseaseOverall survival differenceMOPP chemotherapyDurable remissionsIIB diseaseLate complicationsModality therapyOverall survivalComplete responseMediastinal massSubsequent therapyTumor mortalitySurvival differencesChest radiographsRetrospective analysisMaximal response
1987
The evolution of chemotherapy of lymphomas of adults.
DeVita V. The evolution of chemotherapy of lymphomas of adults. Leukemia 1987, 1: 467-85. PMID: 3312842.Peer-Reviewed Original ResearchDecreasing Risk of Leukemia with Prolonged Follow-up after Chemotherapy and Radiotherapy for Hodgkin's Disease
Blayney D, Longo D, Young R, Greene M, Hubbard S, Postal M, Duffey P, DeVita V. Decreasing Risk of Leukemia with Prolonged Follow-up after Chemotherapy and Radiotherapy for Hodgkin's Disease. New England Journal Of Medicine 1987, 316: 710-714. PMID: 3821809, DOI: 10.1056/nejm198703193161203.Peer-Reviewed Original ResearchConceptsRisk of leukemiaHodgkin's diseaseAcute leukemiaNormal marrow morphologyBone marrow aspirationAcute nonlymphocytic leukemiaSecond neoplasmsMarrow aspirationNonlymphocytic leukemiaMarrow morphologyActuarial analysisPatientsBone marrowFirst treatmentPeak onsetLeukemiaMorphologic changesChemotherapyRadiation treatmentDiseaseComplicationsTreatmentRiskYearsPrevious studies
1986
Twenty years of MOPP therapy for Hodgkin's disease.
Longo D, Young R, Wesley M, Hubbard S, Duffey P, Jaffe E, DeVita V. Twenty years of MOPP therapy for Hodgkin's disease. Journal Of Clinical Oncology 1986, 4: 1295-306. PMID: 3528400, DOI: 10.1200/jco.1986.4.9.1295.Peer-Reviewed Original ResearchConceptsEnd of treatmentHodgkin's diseaseComplete responseDisease patientsLymphocyte-depleted typeHodgkin's disease patientsHigher CR rateResults of treatmentMOPP therapyB symptomsIntercurrent illnessComplete remissionLonger remissionsCR rateHodgkin's lymphomaLonger survivalBiopsy specimensPatientsHigh dosesDiseaseRemissionLymphomaMore cyclesTreatmentLarge cells
1985
Current Management of Hodgkin’s Disease
Behrens B, Young R, DeVita V. Current Management of Hodgkin’s Disease. Drugs 1985, 30: 355-367. PMID: 3905335, DOI: 10.2165/00003495-198530040-00004.Peer-Reviewed Original ResearchConceptsComplete remissionHodgkin's diseaseDurable complete remissionAcute side effectsCombination chemotherapy programsLong-term complicationsPrognosis of patientsImproved treatment approachesProbable cureInduction therapySalvage therapyMost patientsTerm complicationsChemotherapy programSuch patientsStandard radiotherapySpecific therapySide effectsTreatment approachesPatientsCurrent managementCurrent trialDiseaseTherapyRemissionAbnormal coagulation results in patients with hodgkin's disease
Seifter E, Parker R, Gralnick H, Wesley M, DeVita V, Young R, Longo D. Abnormal coagulation results in patients with hodgkin's disease. The American Journal Of Medicine 1985, 78: 942-950. PMID: 3160235, DOI: 10.1016/0002-9343(85)90216-5.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseProthrombin timeAbnormal coagulation test resultsAbnormal coagulation resultsAbnormal test valuesComplete staging evaluationProthrombin time prolongationCoagulation test resultsCourse of diseaseCoagulation factor disordersPartial thromboplastin timeAlkaline phosphatase levelsClotting abnormalitiesAdvanced diseaseConstitutional symptomsMediastinal involvementStaging evaluationCoagulation abnormalitiesAbnormal coagulationEvaluable casesTumor regressionThromboplastin timeFactor disordersHematologic testingInvasive proceduresThe current status of NCI trials in Hodgkin’s disease
Young R, Longo D, Glatstein E, Duffey P, Winkler C, Wiernik P, Devita V. The current status of NCI trials in Hodgkin’s disease. Developments In Oncology 1985, 293-298. DOI: 10.1007/978-1-4613-2607-6_30.Peer-Reviewed Original Research
1984
BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study.
Bakemeier R, Anderson J, Costello W, Rosner G, Horton J, Glick J, Hines J, Berard C, DeVita V. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study. Annals Of Internal Medicine 1984, 101: 447-56. PMID: 6089632, DOI: 10.7326/0003-4819-101-4-447.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBlood Cell CountCarmustineClinical Trials as TopicCombined Modality TherapyCyclophosphamideFemaleGastrointestinal DiseasesHematologic DiseasesHodgkin DiseaseHumansMaleMechlorethamineNeoplasm StagingPeripheral Nervous System DiseasesPrednisoneProcarbazineRandom AllocationVinblastineVincristineConceptsAdvanced Hodgkin's diseaseHodgkin's diseaseUntreated patientsEastern Cooperative Oncology Group studyDuration of complete remissionRandomized prospective studyTreatment of patientsMOPP regimenHematologic toxicityInduction chemotherapyComplete remissionChemotherapy regimensRemission rateNeurological toxicityProspective studyMOPPRemissionTherapeutic benefitChemotherapyPatientsInduction phaseDiseaseToxicityGroup studyDurationSecond malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience.
Tester W, Kinsella T, Waller B, Makuch R, Kelley P, Glatstein E, DeVita V. Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience. Journal Of Clinical Oncology 1984, 2: 762-9. PMID: 6547479, DOI: 10.1200/jco.1984.2.7.762.Peer-Reviewed Original ResearchConceptsSecond malignant neoplasmsHodgkin's diseaseMalignant neoplasmsSolid tumorsNational Cancer Institute ExperienceChronic myeloid leukemiaCases of sarcomaRisk of leukemiaUntreated patientsPatient ageHodgkin's lymphomaMedical recordsInstitute experienceMyeloid leukemiaSimilar riskAge 40Treatment groupsPatientsGreater riskLeukemiaTen yearsDiseaseTumorsLymphomaPositive association
1982
Changing patterns of Hodgkin's disease at autopsy: a 25-year experience at the National Cancer Institute, 1953--1978.
Grogan T, Berard C, Steinhorn S, Hankey B, Kant J, Miliauskas J, Young R, DeVita V. Changing patterns of Hodgkin's disease at autopsy: a 25-year experience at the National Cancer Institute, 1953--1978. Journal Of The National Cancer Institute 1982, 66: 653-65. PMID: 7074636.Peer-Reviewed Original ResearchConceptsResidual Hodgkin's diseaseHodgkin's diseaseVascular invasionTreatment eraCertain histologic typesExtent of diseaseSite of involvementNational Cancer InstituteEffect of treatmentCurative intentLate deathsExtranodal involvementExtranodal spreadPalliative therapyPathologic reviewAnatomic extentComparable incidenceHistologic subtypeHistologic typeInitial diagnosisPathologic findingsHistologic assessmentVascular spreadHistologic appearanceEffect of duration
1981
Long-term follow-up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease
Schilsky R, Sherins R, Hubbard S, Wesley M, Young R, DeVita V. Long-term follow-up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease. The American Journal Of Medicine 1981, 71: 552-556. PMID: 7282743, DOI: 10.1016/0002-9343(81)90205-9.Peer-Reviewed Original ResearchConceptsOvarian failureMOPP chemotherapyOvarian functionChemotherapy-induced ovarian failureAge 25Causes of amenorrheaCompletion of chemotherapyPercent of patientsLong-term followTime of evaluationTime of treatmentPersistent amenorrheaChemotherapy regimenOlder patientsMedian ageHodgkin's diseaseEstradiol levelsSerum gonadotropinPatientsAmenorrheaChemotherapyNormal childrenWomenDiseaseTreatmentThe consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky memorial lecture
Devita V. The consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky memorial lecture. Cancer 1981, 47: 1-13. PMID: 6970069, DOI: 10.1002/1097-0142(19810101)47:1<1::aid-cncr2820470102>3.0.co;2-2.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseLong-term adverse consequencesPresence of symptomsNational Cancer InstituteMOPP programComplete remissionNodular sclerosisHistologic subtypeImmunosuppressive drugsNational mortalityEffective chemotherapyDrug treatmentCancer InstituteChemotherapyDiseaseCarcinogenic effectsAdverse effectsYoung populationMOPPAdverse consequencesImportant negative influenceRemissionSclerosisPatientsPrognosis